Logo

MLC Dx

Small Sequencing Tech and Dx Firms Win More than $6M under Qualifying Therapeutic Discovery Project Program
Premium

Companies developing DNA sequencing and related technologies, as well as firms working on sequencing-based genetic tests, were among almost 3,000 small biotechs who received a total of $1 billion in grants and tax credits under the QTDP program.

People in the News: Sep 3, 2010
Premium

Norrie Russell, Thomas Willis, Malek Faham

Immune Repertoire Profiling Startup MLC Dx Raises $6M in Private Funding Round
Premium

Company executives have a patent pending that describes methods “for using DNA sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions,” according to the recently published patent application.

Paired Ends: Aug 24, 2010
Premium

Thomas Willis, Malek Faham, Lawrence Tabak

MLC Dx Raises $6M in Private Financing

The molecular diagnostics firm currently has a patent application for a method of using DNA sequencing technology for identifying biomarkers of autoimmune disease.
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.